دورية أكاديمية
Preemptive interleukin‐6 blockade in patients with COVID‐19
| العنوان: | Preemptive interleukin‐6 blockade in patients with COVID‐19 |
|---|---|
| المؤلفون: | Guillén, Lucía, Padilla, Sergio, Fernández, Marta, Agulló, Vanesa, García, JoséAlberto, Telenti, Guillermo, García‑Abellán, Javier, Botella, Ángela, Gutiérrez, Félix, Masiá, Mar |
| المصدر: | reponame:Expeditio Repositorio Institucional UJTL ; instname:Universidad de Bogotá Jorge Tadeo Lozano |
| بيانات النشر: | Scientific reports |
| سنة النشر: | 2020 |
| المجموعة: | Expeditio - Repositorio Institucional Universidad de Bogotá Jorge Tadeo Lozano (UTADEO) |
| مصطلحات موضوعية: | Preemptive interleukin‑6, COVID‑19, Patients, Síndrome respiratorio agudo grave, COVID-19, SARS-CoV-2, Coronavirus |
| الوصف: | Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be benefcial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identifed outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score < 3 fulflling pre-defned criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I difered according to tocilizumab response and discriminated fnal in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 9 páginas; application/pdf |
| اللغة: | English |
| تدمد: | 2045-2322 |
| العلاقة: | https://doi.org/10.1038/s41598-020-74001-3Test; http://hdl.handle.net/20.500.12010/14378Test |
| DOI: | 10.1038/s41598-020-74001-3 |
| الإتاحة: | https://doi.org/20.500.12010/14378Test https://doi.org/10.1038/s41598-020-74001-3Test https://hdl.handle.net/20.500.12010/14378Test |
| حقوق: | info:eu-repo/semantics/openAccess ; Abierto (Texto Completo) |
| رقم الانضمام: | edsbas.82EDEB4 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-020-74001-3 |